Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
620 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 758
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇨🇳 ChinaCN-S01 · National Healthcare Security Administration / Ministry of Human Resources and Social Security · Notice on the 2025 National Reimbursement Drug ListOfficialPayment standards, same-generic-name and VBP linkage, transition arrangements and local implementation2025-12-07 / 2026-01-01Latest observed: 2025-12-07🇨🇳 ChinaCN-S02 · National Healthcare Security Administration · Official documents for the 2026 National Reimbursement Drug List adjustment work planOfficialFormal application, renewal and price-bidding rules2026-05-31Latest observed: 2026-05-31🇨🇳 ChinaCN-S03 · National Healthcare Security Administration · Policy interpretation of the 2026 National Reimbursement Drug List adjustment planOfficialTwo-year agreements, the eight-year threshold, renewal and price-bidding changes2026-05-09Latest observed: 2026-05-09🇨🇳 ChinaCN-S04 · National Healthcare Security Administration / National Health Commission · Guiding opinion on the dual-channel management mechanism for negotiated medicinesOfficialDual-channel definition, supply requirements and medical-insurance payment2021-05-10Latest observed: 2021-05-10🇨🇳 ChinaCN-S05 · General Office of the State Council / republished by the National Healthcare Security Administration · Several Opinions on Improving the Drug Price Formation Mechanism (State Council General Office Document [2026] No. 9)OfficialVBP, provincial listing, payment standards, retail, RWE and price governanceIssued 30 Mar 2026; published 14 Apr 2026Latest observed: 2026-04-14🇨🇳 ChinaCN-S06 · National Healthcare Security Administration · Interim Measures for the Administration of Medicines under Basic Medical InsuranceOfficialFoundation for expert review, negotiation, renewal and payment compliance2020-07-31 / 2020-09-01Latest observed: 2020-07-31🇨🇳 ChinaCN-S07 · General Office of the State Council · Opinion on Normalizing and Institutionalizing Centralized Volume-Based Procurement of MedicinesOfficialNational institutional foundation for VBP2021-01-28Latest observed: 2021-01-28🇨🇳 ChinaCN-S08 · National Healthcare Security Administration · Announcement of the National Centralized Drug Procurement Document (GY-YD2025-1)OfficialEntry point for the latest procurement round, participating entities and committed demand2025-09-20Latest observed: 2025-09-20🇨🇳 ChinaCN-S09 · National Medical Products Administration · NMPA Announcement No. 50 of 2026: Good Clinical Practice (2026 Revision)OfficialClinical-evidence quality, participant protection, proportionate risk management, data reliability and traceability, and sponsor/investigator dutiesAnnounced 21 May 2026; published 8 Jun 2026; effective 1 Sep 2026Latest observed: 2026-06-08🇨🇳 ChinaCN-S10 · National Healthcare Security Administration · Questions and answers on the first batch of 2026 medical-insurance payment scopesOfficialImplementation of payment scope and interpretation of clinical scenarios2026-04-17Latest observed: 2026-04-17🇨🇳 ChinaCN-S11 · National Healthcare Security Administration Guidance Center · Draft Guidelines for Comprehensive Real-World Medical-Insurance Value Assessment of Medicines (Trial) for public commentOfficialPolicy status of RWE and boundaries against overstatement2026-01-14Latest observed: 2026-01-14Europe
🇩🇪 GermanyDE-S01 · EMA / EC · Authorisation of medicines; pre-authorisation guidanceOfficialcentralised scope, CHMP/EC roles, EU validityEU centralised legal frameworkLatest observed: current🇩🇪 GermanyDE-S01 · EMA / EC · Authorisation of medicines; pre-authorisation guidanceOfficialcentralised scope, CHMP/EC roles, EU validityEU centralised legal frameworkLatest observed: current🇩🇪 GermanyDE-S02 · BfArM · National procedure; Decentralised ProcedureOfficialBfArM/PEI boundary, DCP/MRP/nationalcurrent German proceduresLatest observed: checked live🇩🇪 GermanyDE-S02 · BfArM · National procedure; Decentralised ProcedureOfficialBfArM/PEI boundary, DCP/MRP/nationalcurrent German proceduresLatest observed: checked live🇩🇪 GermanyDE-S03 · G-BA · Benefit Assessment of Medicinal Products / Ablauf der frühen NutzenbewertungOfficialday-1 dossier, 3+3 months, ACT, month-7 priceAMNOG effective 2011-01-01Latest observed: current 2026🇩🇪 GermanyDE-S03 · G-BA · Benefit Assessment of Medicinal Products / Ablauf der frühen NutzenbewertungOfficialday-1 dossier, 3+3 months, ACT, month-7 priceAMNOG effective 2011-01-01Latest observed: current 2026🇩🇪 GermanyDE-S04 · G-BA / KBV · Additional-benefit categories; early benefit assessmentOfficialextent/certainty, subgroups, resolution fieldscurrentLatest observed: checked live🇩🇪 GermanyDE-S04 · G-BA / KBV · Additional-benefit categories; early benefit assessmentOfficialextent/certainty, subgroups, resolution fieldscurrentLatest observed: checked live🇩🇪 GermanyDE-S05 · G-BA · New medicines: procedural rules after EU assessmentOfficialEU JCA and national AMNOG linkage2025-07Latest observed: current implementation🇩🇪 GermanyDE-S06 · GKV-Spitzenverband · AMNOG negotiations §130b SGB VOfficialfirst 6 months, month 7, negotiation, price rules, mixed price, EU price removalcurrent rulesLatest observed: current through 2026🇩🇪 GermanyDE-S07 · BMG / GKV-SV · Medizinforschungsgesetz; confidential reimbursement amountOfficialR&D eligibility, 9%, confidential amount2024 law; option from 2025Latest observed: temporary to 2028-06-30🇩🇪 GermanyDE-S07 · BMG / GKV-SV · Medizinforschungsgesetz; confidential reimbursement amountOfficialR&D eligibility, 9%, confidential amount2024 law; option from 2025Latest observed: temporary to 2028-06-30🇩🇪 GermanyDE-S08 · G-BA · GKV-FinStG statutory tasks and orphan >€30m current casesOfficialorphan presumption/threshold/reassessmentthreshold change Nov 2022Latest observed: current 2026 cases🇩🇪 GermanyDE-S08 · G-BA · GKV-FinStG statutory tasks and orphan >€30m current casesOfficialorphan presumption/threshold/reassessmentthreshold change Nov 2022Latest observed: current 2026 casesAmericas
🇺🇸 United StatesUS-S01 · FDA · Development & Approval Process / Accelerated ApprovalOfficialapproval, expedited programmes, confirmatory/withdrawal; not coveragecurrent page / AA quarterly data through 2026-03-31Latest observed: 2026🇺🇸 United StatesUS-S02 · CMS · Medicare Coverage Center and Medicare Coverage DatabaseOfficialNCD/LCD/benefit and reasonable-necessary boundarycurrentLatest observed: 2026🇺🇸 United StatesUS-S03 · CMS · Part B Drugs and ASP ReportingOfficialASP reporting/payment; exact product file must be checked2026 quarterly filesLatest observed: 2026🇺🇸 United StatesUS-S04 · CMS · HCPCS Quarterly Coding and OPPS Pass-throughOfficialcoding/payment status, not coverageQ2 2026/current OPPS materialsLatest observed: 2026🇺🇸 United StatesUS-S05 · CMS · Part D Formulary Guidance and Benefit Manual Ch. 6OfficialP&T, review, protected classes and formulary standardsCY2026/current manualLatest observed: 2026🇺🇸 United StatesUS-S06 · CMS · Medicare Drug Price Negotiation: selected drugs and negotiated pricesOfficialMFP selection/price/effectuation; selected products onlyfirst MFP effective 2026-01-01Latest observed: 2026-07🇺🇸 United StatesUS-S07 · CMS · Final CY2026 Part D Redesign Program InstructionsOfficial2026 benefit/liability and selected-drug formulary rule2025-04-07 / CY2026Latest observed: 2025-04-07🇺🇸 United StatesUS-S08 · CMS Medicaid · Medicaid Prescription Drugs / MDRPOfficialNDRA, coverage, AMP/Best Price/URA; state implementation separatecurrent programme and 2026 releasesLatest observed: 2026🇺🇸 United StatesUS-S09 · CMS Medicaid · State Prescription Drug Resources / supplemental rebate agreementsOfficialstate PDL/PA/rebate variation; named state must be checkedcurrent through 2026Latest observed: 2026-05🇺🇸 United StatesUS-S10 · HRSA · 340B Drug Pricing Program — ManufacturersOfficialPPA and ceiling obligations; not payer coveragecurrentLatest observed: 2026🇺🇸 United StatesUS-S11 · FTC · PBM interim report and Rebate Walls reportOfficialofficial market investigation evidence; not a universal contract rule2024 interim / 2025 second reportLatest observed: 2025-01🇺🇸 United StatesUS-S12 · VA · Veterans Health Care Act / PPA and Federal Ceiling PriceOfficialVA statutory agreements/FCP; exact covered drug and contract needed2026 annual guidanceLatest observed: 2026🇺🇸 United StatesUS-S13 · CMS · WAC statutory definition under SSA §1847AOfficialWAC is list price excluding reductions; older explanatory rule, definition currentstatutory definitionLatest observed: current statute🇺🇸 United StatesUS-S14 · CMS · Covered Outpatient Drugs Final RuleOfficialAMP/FUL/acquisition-cost background; current releases supersede specificsCMS-2345-FCLatest observed: current framework🇺🇸 United StatesUS-S15 · U.S. Department of Labor · ERISA/PBM plan oversight materialsOfficialshows ERISA plan/PBM boundary; proposal is not final ruleproposed PBM disclosure rule, 2026-01-30Latest observed: 2026-02-27For education only — not regulatory, pricing or legal advice.